Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Cancer Gene Therapy · August 20, 2026
A consensus or society position rather than new primary data.
This is a comprehensive narrative review of advanced gene editing technologies (CRISPR, base editors, prime editors, and hybrid platforms) applied to oncology, covering molecular mechanisms, cancer-type-specific applications, delivery challenges, and the translational pathway to clinical use. It synthesizes the state of the field but presents no new empirical evidence, primary outcomes, or comparative efficacy data.
Narrative review. Patients with cancer across multiple tumor types; review of published literature and clinical trials. Intervention: Advanced gene editing technologies: CRISPR/Cas systems, base editors, prime editors, PASTE system, Zinc Finger Nucleases, TALENs, and hybrid platforms (ARCUS, MegaTALs, modified recombinases).
Review examines established technologies including Zinc Finger Nucleases, TALENs, and CRISPR/Cas systems (Cas9, Cas12, Cas13) Novel advancements covered include base editors, prime editors, and the PASTE system Hybrid platforms such as ARCUS and MegaTALs are integrated with artificial intelligence and synthetic biology
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides clinicians and researchers with a comprehensive overview of the current landscape and translational status of gene editing in oncology, useful for understanding the scope of emerging therapies and identifying areas where clinical implementation is advancing. However, it does not provide evidence to support specific treatment decisions.
A comprehensive narrative review synthesizing mechanisms, applications, and clinical implementation of gene editing technologies in oncology, without presenting new empirical data or trials.
As stated by the source record.
This review provides clinicians and researchers with a comprehensive overview of the current landscape and translational status of gene editing in oncology, useful for understanding the scope of emerging therapies and identifying areas where clinical implementation is advancing. However, it does not provide evidence to support specific treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Advanced gene editing tools have transformed oncology by facilitating precise molecular therapies aimed at the hereditary basis of cancer. This thorough study examines the mechanisms, applications, and clinical implementation of advanced genome editing technologies in cancer treatment. This review commences with the molecular principles of genome editing and DNA repair mechanisms, systematically analyzing established technologies such as Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases, and various CRISPR/Cas systems (Cas9, Cas12, Cas13), in addition to novel advancements including base editors, prime editors, and the PASTE system. Additionally, hybrid platforms such as ARCUS, MegaTALs, and modified recombinases are examined, highlighting their amalgamation with artificial intelligence, biosensors, and synthetic biology concepts. The study outlines significant applications including functional genomics, disease modeling, synthetic lethality screening, and direct therapeutic interventions, with a specific focus on CAR-T cell engineering and immune checkpoint regulation. Applications unique to various cancer types are thoroughly examined throughout lung, breast, colorectal, hematologic, liver, pancreatic, head & neck, esophageal, prostate, gastric, and brain cancers. Significant obstacles such as delivery optimization via viral and non-viral vectors, tumor-specific targeting, off-target effects, immunogenicity, and ethical issues related to germline vs somatic editing are comprehensively examined. The translational landscape is analyzed via current clinical trials, regulatory structures, and the incorporation of organoid models and patient-derived xenografts for the advancement of personalized therapies. This review highlights the transformative impact of gene editing on cancer medicine, advancing toward more accurate, effective, and personalized therapeutic approaches.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.